Day 3 :
President of ISIN
Keynote: Effects of the consumption of Lactobacillus coryniformis CECT5711 strain on the immune response and intestinal function of healthy adults
Time : 10:00-10:30
Ascension Marcos got her PhD at the School of Pharmacy at the Complutense University in Madrid, Spain (UCM) in 1982 and Master in Clinical Analysis by UCM in 1986, and got a grant at the Spanish National Research Council (CSIC). She was the Head of the Institute of Nutrition and Food Technology at the Mixed Center CSIC-UCM (1998-2002). She is the leader of the Immunonutrition Research Group at the Department of Metabolism and Nutrition at CSIC since 1987. She achieved the highest category at CSIC as a Research Professor in 2006 and her scientific consolidation has been recognized for 5 six-year terms since 1985. Shernis a pioneer in the field of Immunonutrition in Spain, Founder and President of the International Forum of Immunonutrition for Education and Research (i-FINER) since 2007. In 2014 the i-FINER group has developed the International Society for Immunonutrition (ISIN), she being also the President.
Background: Among the various health-promoting functions of probiotics, much attention has been paid to their immunological function, specifically the prevention of infections, which seems to be related with their capability to modulate de intestinal microbiota.
Objective: Since effects of probiotics are strain-dependent, the main objective of this study was to assess the effect of Lactobacillus coryniformis CECT5711 (Lc) on both immune response and intestinal function of healthy adults during 6 weeks of treatment in a Hepatitis A vaccine model.
Methods: One hundred twenty three volunteers were randomized into 1) Placebo group (n=40), which received a daily capsule containing maltodextrin, 2) Probiotic group (n=41), which received a daily capsule of Lc (109 cfu/day) and 3) Mixed group (n=42), which received Lc for 2wk (prior to vaccination) and then placebo. Blood and stool samples were taken in 3 visits (V): at the beginning (V1), after two weeks of treatment just before the vaccination (V2) and at the end of the study (V3). At each V, lymphocyte subset counts, phagocytic capacity, natural killer activity, serum cytokine levels and microbiota composition by qPCR were analyzed, whereas specific HAV antibodies were measured just before and after the vaccine by ELISA tests (at the beginning and at the end of the study). Intestinal habits (bowel movements and stool consistency with the Bristol scale: types 1-2 hard, types 3, 4 and 5 normal, types 6-7 soft watery) were evaluated by a dairy record, and the intestinal symptoms appearance (nausea, borborigms, bloating, intestinal pain and flatulence) weekly in a single specific day. One-way ANOVA with Bonferroni post-hoc tests and lineal mixed models were performed for normally-distributed variables and Kruskal-Wallis with Mann-Whitney U test, Friedman’s 2-way ANOVA and Kendall’s coefficient of concordance for non-parametric variables. Chi square test was used to evaluate the frequency of intestinal symptoms between groups of treatments and visits.
Results: Specific HAV antibodies were significantly higher in the mixed group compared to the control group (P=0.017). Memory T-helper lymphocytes increased in V3 vs V1 (P=0.032) in the probiotic group. No differences were found in innate immunity parameters and cytokine concentrations, as well as in the intestinal microbiota composition, bowel movements and stool consistency. However, a trend to a lower appearance of total symptoms were observed in the last 4 weeks of intervention in the probiotic and mixed groups compared to the placebo group (82.9% y 80.9 % vs 97.5%) (P=0.054).
Conclusion: These results suggest that Lactobacillus coryniformis CECT5711 could improve vaccine efficiency by enhancing increasing antibody response and perhaps immunological memory. There were no remarkable effects on the intestinal function probably because they are healthy adults with a very low appearance of intestinal disorder symptoms. Even so, the intervention with this strain led to a lower tendency of symptoms appearance compared to the placebo group.
Danone Nutricia Research, Singapore
Time : 10:30-11:00
Shugui Wang has completed her PhD at National University of Singapore. She worked as a Post-doctoral Researcher at Genome Institute of Singapore working closely with Martin Hibberd. Her research focus was on gut micro-biota in relation to host’s health and infection. Thereafter at the National Cancer Centre Singapore, she continued her research passion with Sven Pettersson on gut-brain axis focusing on gut micro-biota and brain functions. She is currently working at Danone Nutricia Research.
The acquisition of intestinal micro-biota after birth has a defining impact on the development and function of immune and metabolic systems integral to health and homeostasis. During first 1000 days of life, the gut micro-biota of infants quickly becomes remarkably diverse and rich. Interestingly, the neurodevelopmental window is paralleled with the major shifts in the infant micro-biota. Disruptions in evolving gut micro-biota during this critical period can impact postnatal brain development. Probiotics are believed to balance gut micro-biota and benefit the host’s health. They have been found to relieve mental disorders, possibly through lowering levels of pro-inflammatory cytokines in the host and decreasing stress-induced corticosterone production, whilst concurrently increasing bacterial metabolites such as tryptophan. It has been recently suggested that probiotic supplementation during the first six months of life may reduce the risk of development of neuropsychiatric disorders in later life. There is increasing evidence that probiotics contribute to brain development and especially during the first 1000 days of life. However, the mechanisms how probiotics benefit brain development still need further investigation.